MX344153B - Proceso para la preparación de sales de pirrolidinio. - Google Patents

Proceso para la preparación de sales de pirrolidinio.

Info

Publication number
MX344153B
MX344153B MX2011010657A MX2011010657A MX344153B MX 344153 B MX344153 B MX 344153B MX 2011010657 A MX2011010657 A MX 2011010657A MX 2011010657 A MX2011010657 A MX 2011010657A MX 344153 B MX344153 B MX 344153B
Authority
MX
Mexico
Prior art keywords
preparing
pyrrolidinium salts
independently
pyrrolidinium
salts
Prior art date
Application number
MX2011010657A
Other languages
English (en)
Other versions
MX2011010657A (es
Inventor
Allmendinger Thomas
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42200985&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX344153(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2011010657A publication Critical patent/MX2011010657A/es
Publication of MX344153B publication Critical patent/MX344153B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Un proceso de dos pasos para la preparación de un compuesto de la fórmula 1: (ver fórmula (I)) en una forma de sal o zwiteriónica, en donde R1 y R2 son cada uno independientemente cicloalquilo de 3 a 8 átomos de carbono, o arilo de 6 a 10 átomos de carbono; y R3 y R4 son cada uno independientemente alquilo de 1 a 8 átomos de carbono. El proceso minimiza la variación en las proporciones relativas de los diaestereoisómeros.
MX2011010657A 2009-04-09 2010-04-07 Proceso para la preparación de sales de pirrolidinio. MX344153B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16797709P 2009-04-09 2009-04-09
PCT/EP2010/054610 WO2010115937A1 (en) 2009-04-09 2010-04-07 Process for preparing pyrrolidinium salts

Publications (2)

Publication Number Publication Date
MX2011010657A MX2011010657A (es) 2011-10-21
MX344153B true MX344153B (es) 2016-12-07

Family

ID=42200985

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011010657A MX344153B (es) 2009-04-09 2010-04-07 Proceso para la preparación de sales de pirrolidinio.

Country Status (14)

Country Link
US (1) US20120022127A1 (es)
EP (1) EP2417106B1 (es)
JP (2) JP5902612B2 (es)
KR (1) KR101290893B1 (es)
CN (1) CN102388021B (es)
AU (1) AU2010233772B2 (es)
BR (1) BRPI1016083A8 (es)
CA (1) CA2758100C (es)
ES (1) ES2617680T3 (es)
MX (1) MX344153B (es)
PL (1) PL2417106T3 (es)
PT (1) PT2417106T (es)
RU (1) RU2554878C2 (es)
WO (1) WO2010115937A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2580195B1 (en) * 2010-06-14 2014-12-03 Chiesi Farmaceutici S.p.A. Crystal form of glycopyrronium chloride
CN102627595A (zh) * 2012-03-09 2012-08-08 徐奎 一种制备格隆溴铵的方法
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
CN105026369A (zh) * 2013-02-28 2015-11-04 德米拉股份有限公司 格隆铵盐
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
CN103553996B (zh) * 2013-11-13 2016-01-20 北京三泉医药技术有限公司 抗胆碱药物组合物
CN103819384A (zh) * 2013-12-05 2014-05-28 广东嘉博制药有限公司 一种格隆溴铵的制备方法
US9926270B2 (en) 2014-08-20 2018-03-27 Dermira, Inc. Process for production of glycopyrronium tosylate
JP6502501B2 (ja) 2014-09-09 2019-04-17 ベクトゥラ・リミテッド グリコピロレートを含む製剤、方法、及び装置
CN107304178B (zh) * 2016-04-21 2020-03-27 辽宁药联制药有限公司 一种毒蕈碱受体拮抗剂格隆溴铵手性对映体的制备方法
EP3494106B1 (en) 2016-08-02 2022-07-20 Journey Medical Corporation Processes for making, and methods of using, glycopyrronium compounds
CN107915666A (zh) * 2016-10-09 2018-04-17 四川海思科制药有限公司 一种格隆溴铵化合物
US10954191B2 (en) 2017-03-12 2021-03-23 Sol-Gel Technologies Ltd. Process for the preparation of glycopyrrolate tosylate
WO2019021290A1 (en) 2017-07-27 2019-01-31 Sol-Gel Technologies Ltd PROCESS FOR THE PREPARATION OF GLYCOPYRROLATE TOSYLATE
WO2020148777A1 (en) * 2019-01-14 2020-07-23 Neon Laboratories Limited Process for preparation of glycopyrrolate intermediate
CN111349036B (zh) * 2020-03-13 2022-03-08 安徽恒星制药有限公司 一种格隆溴铵的替代物及其制备方法和医药用途
WO2022079194A1 (en) 2020-10-14 2022-04-21 Pcas Process for the production of glycopyrronium tosylate

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
DE2046659A1 (es) 1970-01-28 1972-03-23
FR2081497B1 (es) * 1970-02-09 1974-08-02 Sandoz Sa
IT1016489B (it) 1974-03-18 1977-05-30 Isf Spa Inalatore
ATE193455T1 (de) 1995-12-07 2000-06-15 Jago Pharma Ag Inhalator zur mehrfachen dosisweisen abgabe eines pharmakologischen trockenpulvers
NZ331361A (en) 1996-02-21 2000-01-28 Schering Corp Powder inhaler including swirl means for changing the flow direction of the powder and chimney means for reversing the flow direction
US6613795B2 (en) * 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
ES2206021B1 (es) * 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
AT412088B (de) * 2002-12-18 2004-09-27 Pharmacon Forschung & Beratung Gmbh Verfahren zur herstellung der r,r oder s,s konfigurierten glycopyrronium-isomere
ES2239546B1 (es) 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0504463D0 (en) * 2005-03-03 2005-04-13 Arakis Ltd Method of crystallisation and purification
US7399861B2 (en) 2005-11-10 2008-07-15 Bodor Nicholas S Soft anticholinergic esters
GB0525254D0 (en) * 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
AP2008004537A0 (en) 2005-12-30 2008-08-31 Ranbaxy Lab Ltd Muscarinic receptor antagonists
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds

Also Published As

Publication number Publication date
CA2758100C (en) 2017-08-29
BRPI1016083A2 (pt) 2016-05-10
KR20120013370A (ko) 2012-02-14
RU2554878C2 (ru) 2015-06-27
WO2010115937A1 (en) 2010-10-14
AU2010233772A1 (en) 2011-10-06
AU2010233772B2 (en) 2014-04-24
RU2011145051A (ru) 2013-05-20
CN102388021A (zh) 2012-03-21
PT2417106T (pt) 2017-02-13
JP2015007081A (ja) 2015-01-15
JP2012523390A (ja) 2012-10-04
MX2011010657A (es) 2011-10-21
BRPI1016083A8 (pt) 2017-10-10
JP5902612B2 (ja) 2016-04-13
PL2417106T3 (pl) 2017-05-31
CA2758100A1 (en) 2010-10-14
CN102388021B (zh) 2015-02-18
KR101290893B1 (ko) 2013-07-29
EP2417106B1 (en) 2016-11-30
EP2417106A1 (en) 2012-02-15
US20120022127A1 (en) 2012-01-26
ES2617680T3 (es) 2017-06-19

Similar Documents

Publication Publication Date Title
MX344153B (es) Proceso para la preparación de sales de pirrolidinio.
MY149648A (en) Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
TN2012000401A1 (en) Heterocyclic compound
MX2010002419A (es) (ciclopropilfenil) feniloxamidas, metodo para su produccion y uso como un medicamento.
MX2014001595A (es) Compuestos de imidazol, composiciones y metodos de uso.
MY158982A (en) Heterocyclic compound
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
MX341133B (es) Compuestos y metodos para la inhibición de hdac.
MX2009008264A (es) Compuestos espiro heterociclicos.
EA201000883A1 (ru) Производные индолинона и способ их получения
MX2012003539A (es) Derivados de indol como moduladores de los canales de calcio activados por la liberacion de calcio (crac).
TN2012000248A1 (en) Novel spiropiperidine compounds
CY1119121T1 (el) Αμορφο αλας ενος μακροκυκλικου αναστολεα του hcv
MX2011009127A (es) Nicotinamidas sustituidas como moduladores de kcnq2/3.
MX2015001246A (es) Ibrutinib deuterado.
MX2011011733A (es) Inhiibidores de dihidroorotato deshidrogenasa como compuestos virostaticos.
MX2012006805A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.
JO2673B1 (en) Diosmetin compounds, method of preparation and pharmaceutical compositions
MX2012008141A (es) Compuestos y metodos.
IN2012DN00765A (es)
NZ700356A (en) Pyrazole compounds as sglt1 inhibitors
MX2010004487A (es) Derivados lactamicos sustituidos y sus usos para glaucoma e hipertension ocular.
TW200738704A (en) New process for the production of tiotropium salts
GB201305247D0 (en) Amide Compounds
MX359363B (es) Dihidroetorfina y su preparacion.

Legal Events

Date Code Title Description
FG Grant or registration